Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 10/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 3/20 | 0.36 |
| ▸ | DDO | Q99489 | 2/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.34 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.34 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.34 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ATAD2 | Q6PL18 | 8/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12970080 | 0.84 | BRD4 (0.43) | BRD4DAODDOGRIN2DGRIN3B | |
| SCHEMBL4007864 | 0.79 | GRIN1 (0.38) | DAODDOGRIN2DGRIN3BGRIN1 | |
| SCHEMBL22198970 | 0.79 | HRH4 (0.45) | BRD4DAODDOGRIN2DGRIN3B | |
| SCHEMBL29267034 | 0.78 | IDO1 (0.36) | IDO1 | |
| SCHEMBL24610986 | 0.74 | ALDH1A1 (0.52) | KMT2A | |
| SCHEMBL12970315 | 0.74 | GRIN2D (0.47) | BRD4DAODDOGRIN2DGRIN3B | |
| SCHEMBL12970395 | 0.74 | DAO (0.65) | BRD4DAODDOHSD17B10ATAD2 | |
| SCHEMBL25377837 | 0.72 | KDM4E (0.44) | BRD4DAODDOGRIN2DGRIN3B | |
| SCHEMBL30979292 | 0.72 | KDM4E (0.44) | BRD4DAODDOGRIN2DGRIN3B | |
| SCHEMBL2171366 | 0.71 | CA12 (0.55) | IDO1DAODDOKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170291875-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | UCL BUSINESS PLC (GB) | 2017-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291875-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | BRD4, BRPF3, BRD3 | BRD4 1/4885IDO1 2665/4885DAO 4344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.